EGFR and non-small cell lung carcinoma: To elucidate the epigenetic mechanisms by which NSCLCs acquire resistance to EGFR-TKIs, we treated two NSCLC/ER cell lines, namely, the PC9/ER and HCC827/ER cell lines, with a series of epigenetic enzyme inhibitors at different pharmacological concentrations (0, 5, and 10 μM).